JP2010513567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513567A5 JP2010513567A5 JP2009543169A JP2009543169A JP2010513567A5 JP 2010513567 A5 JP2010513567 A5 JP 2010513567A5 JP 2009543169 A JP2009543169 A JP 2009543169A JP 2009543169 A JP2009543169 A JP 2009543169A JP 2010513567 A5 JP2010513567 A5 JP 2010513567A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- compound according
- aliphatic
- con
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 68
- 125000001931 aliphatic group Chemical group 0.000 claims description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 201000002364 leukopenia Diseases 0.000 claims description 8
- 231100001022 leukopenia Toxicity 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000001118 alkylidene group Chemical group 0.000 claims description 6
- 125000005605 benzo group Chemical group 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- -1 —OR Chemical group 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000005938 2,3-dihydro-1H-isoindolyl group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 0 *c1c(*)[n]nc1* Chemical compound *c1c(*)[n]nc1* 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 150000001539 azetidines Chemical class 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87572906P | 2006-12-19 | 2006-12-19 | |
| US95302707P | 2007-07-31 | 2007-07-31 | |
| PCT/US2007/088058 WO2008077086A1 (en) | 2006-12-19 | 2007-12-19 | Aminopyrimidines useful as inhibitors of protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513567A JP2010513567A (ja) | 2010-04-30 |
| JP2010513567A5 true JP2010513567A5 (enExample) | 2011-01-13 |
Family
ID=39226891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543169A Pending JP2010513567A (ja) | 2006-12-19 | 2007-12-19 | プロテインキナーゼの阻害剤として有用なアミノピリミジン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8426425B2 (enExample) |
| EP (1) | EP2099787B1 (enExample) |
| JP (1) | JP2010513567A (enExample) |
| AT (1) | ATE474835T1 (enExample) |
| AU (1) | AU2007333650A1 (enExample) |
| CA (1) | CA2673353A1 (enExample) |
| DE (1) | DE602007007985D1 (enExample) |
| ES (1) | ES2347721T3 (enExample) |
| MX (1) | MX2009006690A (enExample) |
| NZ (1) | NZ577768A (enExample) |
| WO (1) | WO2008077086A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| WO2008046919A2 (en) | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| CA2668429A1 (en) | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| NZ577768A (en) | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| CN101663295B (zh) | 2007-03-09 | 2014-11-05 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的氨基嘧啶类化合物 |
| JP5393489B2 (ja) | 2007-03-09 | 2014-01-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
| NZ579483A (en) | 2007-03-09 | 2012-07-27 | Vertex Pharma | Aminopyridines useful as inhibitors of protein kinases |
| MX2009011059A (es) | 2007-04-13 | 2009-11-26 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
| WO2008137619A2 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| AU2008247594A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| WO2009018415A1 (en) * | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| CN101768111B (zh) * | 2009-01-07 | 2012-12-26 | 上海开拓者化学研究管理有限公司 | 一种2-氯-5-氟吡啶-3-甲酸的制备方法 |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| KR20160060100A (ko) * | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| PL3089971T3 (pl) | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Związki i sposoby ich zastosowania |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| WO2018106641A1 (en) * | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
| US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| DE2458965C3 (de) * | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
| DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
| DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2203517A1 (en) * | 1994-11-10 | 1996-05-23 | Alan M. Laibelman | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| JP2000026421A (ja) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
| ATE245641T1 (de) * | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
| CA2339188A1 (en) * | 1998-08-21 | 2000-03-02 | Dupont Pharmaceuticals Company | Isoxazolo¬4,5-d|pyrimidines as crf antagonists |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| JP4783532B2 (ja) * | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| KR20030024659A (ko) * | 2000-02-17 | 2003-03-26 | 암겐 인코포레이티드 | 키나제 억제제 |
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| BR0111754A (pt) * | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DE60122176T2 (de) * | 2000-09-15 | 2007-07-05 | Vertex Pharmaceuticals Inc., Cambridge | Isoxazole und ihre verwendung als erk-inhibitoren |
| US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DE10061863A1 (de) * | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| BR0116493A (pt) * | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| MXPA03008888A (es) * | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
| DE60214701T2 (de) * | 2001-04-13 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen |
| EP1383771A1 (en) * | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
| JP4316893B2 (ja) * | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| CA2450769A1 (en) * | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| CA2452603A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| US6698980B2 (en) * | 2001-07-30 | 2004-03-02 | Stewart Mining Products Inc. | Rock stabilizing apparatus and method |
| ATE466581T1 (de) * | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| US6846928B2 (en) * | 2002-03-15 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7863282B2 (en) | 2003-03-14 | 2011-01-04 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| WO2003077921A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
| AU2003225800A1 (en) * | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
| US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| MXPA05001367A (es) | 2002-08-02 | 2005-04-28 | Vertex Pharma | Composiciones de pirazol utiles como inhibidores de gsk-3. |
| ES2328820T3 (es) | 2003-10-17 | 2009-11-18 | Astrazeneca Ab | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. |
| US7737151B2 (en) | 2005-08-18 | 2010-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
| WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
| BRPI0616630B8 (pt) | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | compostos de pirazol substituídos |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| ATE508126T1 (de) * | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| CA2668429A1 (en) * | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| NZ577768A (en) | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| NZ579483A (en) | 2007-03-09 | 2012-07-27 | Vertex Pharma | Aminopyridines useful as inhibitors of protein kinases |
| CN101663295B (zh) | 2007-03-09 | 2014-11-05 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的氨基嘧啶类化合物 |
| JP5393489B2 (ja) | 2007-03-09 | 2014-01-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
| MX2009010037A (es) | 2007-03-20 | 2009-11-05 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
| EP2148931A2 (en) | 2007-04-17 | 2010-02-03 | Vertex Pharmaceuticals Incorporated | Drug discovery methods for aurora kinase inhibitors |
| CA2688584A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| WO2008137619A2 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| AU2008247594A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| AU2008257044A1 (en) | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| SI3330255T1 (sl) | 2009-03-20 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi |
-
2007
- 2007-12-19 NZ NZ577768A patent/NZ577768A/en not_active IP Right Cessation
- 2007-12-19 DE DE602007007985T patent/DE602007007985D1/de active Active
- 2007-12-19 EP EP07855256A patent/EP2099787B1/en active Active
- 2007-12-19 WO PCT/US2007/088058 patent/WO2008077086A1/en not_active Ceased
- 2007-12-19 JP JP2009543169A patent/JP2010513567A/ja active Pending
- 2007-12-19 CA CA002673353A patent/CA2673353A1/en not_active Abandoned
- 2007-12-19 AT AT07855256T patent/ATE474835T1/de active
- 2007-12-19 AU AU2007333650A patent/AU2007333650A1/en not_active Abandoned
- 2007-12-19 MX MX2009006690A patent/MX2009006690A/es active IP Right Grant
- 2007-12-19 ES ES07855256T patent/ES2347721T3/es active Active
-
2009
- 2009-06-17 US US12/486,235 patent/US8426425B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 US US13/798,875 patent/US20140256703A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509231A5 (enExample) | ||
| USRE47739E1 (en) | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | |
| CA2422371A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| CN104470921B (zh) | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP5592890B2 (ja) | ピロロトリアジンキナーゼ阻害剤 | |
| JP2004509118A5 (enExample) | ||
| JP2019535730A (ja) | ピラゾロ‐ヘテロアリール誘導体、その製造方法及び医学的用途 | |
| IL263752A (en) | Training modulating compounds | |
| JP2004512277A5 (enExample) | ||
| JP2010520886A5 (enExample) | ||
| JP2010520887A5 (enExample) | ||
| JP2010520889A5 (enExample) | ||
| JP2004518743A5 (enExample) | ||
| TW200918528A (en) | DNA-PK inhibitors | |
| CA2432303A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| JP2015522028A (ja) | 化合物とその治療用途 | |
| JP2020518672A (ja) | キナーゼ阻害活性を有する化合物、その製造方法及び用途 | |
| JP2004525075A5 (enExample) | ||
| JP2016510793A (ja) | 大環状ｌｒｒｋ２キナーゼ阻害剤 | |
| JP2022528780A (ja) | 治療的使用のためのキナーゼ阻害剤としての複素環式化合物 | |
| CN116444492B (zh) | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 | |
| JP2022527270A (ja) | イソチアゾリジン１，１－ジオキシド及び１，４－ブタンスルトン含有ラパマイシン誘導体並びにその使用 | |
| CN113518779B (zh) | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 | |
| CA2953004A1 (en) | Aromatic heterocyclic derivatives and pharmaceutical applications thereof | |
| JP6736545B2 (ja) | 大環状ｒｉｐ２キナーゼ阻害剤 |